These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 25564053

  • 1. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
    Wang M, Zhang L, Zhao X, Liu J, Chen Y, Wang C.
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
    [Abstract] [Full Text] [Related]

  • 2. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 3. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
    Sun X, Xu Y, Wang Y, Chen Q, Liu L, Bao Y.
    Med Sci Monit; 2018 May 15; 24():3193-3203. PubMed ID: 29763936
    [Abstract] [Full Text] [Related]

  • 4. Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
    Xiang M, Jiang HG, Shu Y, Chen YJ, Jin J, Zhu YM, Li MY, Wu JN, Li J.
    Int J Biol Sci; 2020 May 15; 16(9):1536-1550. PubMed ID: 32226300
    [Abstract] [Full Text] [Related]

  • 5. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
    Zhou Y, Zhang S, Li K, Li QW, Zhou FZ, Li ZY, Ma H, Dong XR, Liu L, Wu G, Meng R.
    Zhonghua Zhong Liu Za Zhi; 2016 Feb 15; 38(2):100-4. PubMed ID: 26899328
    [Abstract] [Full Text] [Related]

  • 6. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    Biochem Biophys Res Commun; 2013 Feb 15; 431(3):623-9. PubMed ID: 23266614
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N, Zhang Q, Fang S, Han X, Wang Z.
    Oncotarget; 2017 Feb 07; 8(6):9134-9143. PubMed ID: 27852073
    [Abstract] [Full Text] [Related]

  • 8. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
    Liu T, Jin L, Lu W, Gan H, Lin Z, Chen M, Liu J, Zhang F, Wang S, Zhang H, Deng W, Chen H.
    J Exp Clin Cancer Res; 2019 Apr 05; 38(1):148. PubMed ID: 30953548
    [Abstract] [Full Text] [Related]

  • 9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 10. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.
    Clin Cancer Res; 2007 Mar 01; 13(5):1540-51. PubMed ID: 17332300
    [Abstract] [Full Text] [Related]

  • 11. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R, Zhou S, Xia B, Zhang CY, Hai P, Zhe H, Wang YY.
    BMC Cancer; 2016 Jul 18; 16():491. PubMed ID: 27431492
    [Abstract] [Full Text] [Related]

  • 12. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC, Liang X, Liu ZY, Cui J, Liu Y, Jing L, Jiang LL, Ma JQ, Han LL, Guo QQ, Yang CC, Wang J, Wu T, Nan KJ, Yao Y.
    Oncol Rep; 2015 Jan 18; 33(1):239-49. PubMed ID: 25370413
    [Abstract] [Full Text] [Related]

  • 13. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [Abstract] [Full Text] [Related]

  • 14. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 15; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 15. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
    Li K, Zhou F, Zhou Y, Zhang S, Li Q, Li Z, Liu L, Wu G, Meng R.
    Int J Mol Med; 2019 Aug 15; 44(2):437-446. PubMed ID: 31173177
    [Abstract] [Full Text] [Related]

  • 16. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation.
    Wang G, Zhao J, Zhang M, Wang Q, Chen B, Hou Y, Lu K.
    Int J Nanomedicine; 2019 Aug 15; 14():4503-4515. PubMed ID: 31417255
    [Abstract] [Full Text] [Related]

  • 17. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 18. Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
    Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K.
    Mol Oncol; 2017 Jun 01; 11(6):670-681. PubMed ID: 28388009
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.
    Oncotarget; 2017 Apr 04; 8(14):23020-23032. PubMed ID: 28416737
    [Abstract] [Full Text] [Related]

  • 20. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 04; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.